Visceral fat reduction by enteric-coated lactoferrin
-
An interesting study from Japan.
Lactoferrin (LF) is a multifunctional glycoprotein found in mammalian breast milk. Its primary function was thought to be antimicrobial or immunomodulatory activity because it is present at high concentrations in breast milk. In recent years, several studies have shown other functions of LF, including modulation of lipid metabolism. The purpose of this review is to summarize the current knowledge of the effects of LF on systemic lipid metabolism. In vitro studies have revealed anti-adipogenic and lipolytic activities of LF against adipocytes. In vivo studies have also demonstrated that LF can decrease plasma, hepatic triglycerides and cholesterol and can reduce visceral fat. In human epidemiological studies, the circulating LF concentration is reportedly inversely associated with BMI, waist:hip ratios, fasting triglyceride and glucose concentrations and positively associated with insulin sensitivity. Moreover, oral supplementation with enteric-coated LF reduced visceral fat accumulation in a randomized controlled trial.
-
Lactoferrin (LF), a multifunctional glycoprotein in mammalian milk, is reported to exert a modulatory effect on lipid metabolism. The aim of the present study was to elucidate whether enteric-coated LF (eLF) might improve visceral fat-type obesity, an underlying cause of the metabolic syndrome. Using a double-blind, placebo-controlled design, Japanese men and women (n 26; aged 22–60 years) with abdominal obesity (BMI . 25 kg/m2, and visceral fat area (VFA) . 100 cm2) consumed eLF (300 mg/d as bovine LF) or placebo tablets for 8 weeks. Measurement of the total fat area, VFA and subcutaneous fat area from computed tomography images revealed a significant reduction in VFA (214·6 cm2) in the eLF group, as compared with the placebo controls (21·8 cm2; P¼0·009 by ANCOVA). Decreases in body weight, BMI and hip circumference in the eLF group (21·5 kg, 20·6 kg/m2, 22·6 cm) were also found to be significantly greater than with the placebo (þ1·0 kg, þ0·3 kg/m2, 20·2 cm; P¼0·032, 0·013, 0·041, respectively). There was also a tendency for a reduction in waist circumference in the eLF group (24·4 cm) as compared with the placebo group (20·9 cm; P¼0·073). No adverse effects of the eLF treatment were found with regard to blood lipid or biochemical parameters. From these results, eLF appears to be a promising agent for the control of visceral fat accumulation.
-
Just for review:
-
What about liposomal lactoferrin? Hard to find any enteric-coated products in the EU.
Also, is apolactoferrin better or worse from a Peaty perspective? They have different effects on iron metabolism.
-
@revenant - It hard to find enteric-coated here in the US as well. I found one product on Amazon that is produced in Japan. It is called "Doctors Mega Lactoferrin – 120 Enteric-Coated Tablets".
As shown in the image above, the coating delivers the lactoferrin to the colon.
"Without a realistic view of where you are, you can't expect to go anywhere." Ray Peat (1936-2022) 👀
☂️ -
See another thread about enteric-coated lactoferrin. I was hoping not to find any negative effects of translocating the lactoferrin delivery to the colon.
